Currently - right now Imugene has no trials that are measured against the current SOC. Moreover the Ph2/3 Registrational trial may not be measured against the current SOC. We don't know yet do we? Azer Cell - may come to market - but it may be as a 2nd in line or 3rd in line etc.
I suspect the PH2/3 rego trial will be for relapsed patients, a certain pool of patients. If so this will mean it will not replace SOC, anyway we will see.
IMU Price at posting:
3.9¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)